Matrix Approach Assessment of Cabotegravir Drug–Drug Interactions with OAT1/OAT3 Substrates and UGT1A1/UGT1A9 Inhibitors Using Physiologically-Based Pharmacokinetic Modeling

Matrix Approach Assessment of Cabotegravir Drug–Drug Interactions with OAT1/OAT3 Substrates and UGT1A1/UGT1A9 Inhibitors Using Physiologically-Based Pharmacokinetic Modeling

<b>Background/Objective:</b> Cabotegravir (CAB), available as an oral tablet and as a long-acting (LA) nanosuspension for intramuscular injection, is approved as a combination therapy for the treatment, and as a monotherapy for the prevention, of HIV-1 infection. People living with HIV m...

Full description

Saved in:
Bibliographic Details
Main Authors: Helen Tracey, Simon T. Bate, Susan Ford, Parul Patel, Jackie Bloomer, Aarti Patel, Kunal S. Taskar
Format: Article
Language:English
Published: MDPI AG 2025-04-01
Series:Pharmaceutics
Subjects:
PBPK modeling
cabotegravir
OAT1
OAT3
UGT1A1
UGT1A9
Online Access:https://www.mdpi.com/1999-4923/17/4/531
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1999-4923/17/4/531

Similar Items